“The current condition has uncovered some structural weaknesses in the EU’s medicines offer chain and a superior dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides said. She suggested that supply chain issues be dealt with within an EU pharmaceutical tactic anticipated to get introduced by the top